Ken Griffin’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-69,746
| Closed | -$15K | – | 10367 |
|
|
2018
Q3 | $15K | Sell |
69,746
-66,297
| -49% | -$15.3K | ﹤0.01% | 9072 |
|
|
2018
Q2 | $35K | Sell |
136,043
-258,612
| -66% | -$67.2K | ﹤0.01% | 8527 |
|
|
2018
Q1 | $99K | Buy |
+394,655
| New | +$109K | ﹤0.01% | 7717 |
|
|
2016
Q3 | – | Sell |
-1,051
| Closed | -$10K | – | 8351 |
|
|
2016
Q2 | $10K | Sell |
1,051
-2,176
| -67% | -$22.4K | ﹤0.01% | 6731 |
|
|
2016
Q1 | $37K | Buy |
+3,227
| New | +$36.3K | ﹤0.01% | 6332 |
|
|
2015
Q3 | – | Sell |
-290
| Closed | -$5K | – | 9724 |
|
|
2015
Q2 | $5K | Buy |
+290
| New | +$5.58K | ﹤0.01% | 8557 |
|
|
2015
Q1 | – | Sell |
-1,465
| Closed | -$43K | – | 9344 |
|
|
2014
Q4 | $43K | Buy |
1,465
+912
| +165% | +$26.2K | ﹤0.01% | 7321 |
|
|
2014
Q3 | $20K | Sell |
553
-162
| -23% | -$6.24K | ﹤0.01% | 7464 |
|
|
2014
Q2 | $32K | Buy |
715
+623
| +677% | +$30.1K | ﹤0.01% | 7055 |
|
|
2014
Q1 | $5K | Sell |
92
-1,776
| -95% | -$86.9K | ﹤0.01% | 7672 |
|
|
2013
Q4 | $69K | Buy |
1,868
+1,462
| +360% | +$138K | ﹤0.01% | 5872 |
|
|
2013
Q3 | $42K | Buy |
+406
| New | +$44.6K | ﹤0.01% | 5891 |
|
Other funds holding IMUC
Ken Griffin's IMUC Position: Q4 2018 in Review
Ken Griffin sold out of ImmunoCellular Therapeutics, Ltd. (IMUC) in Q4 2018, closing a stake of 69,746 shares — an estimated $15K sold.
Ken Griffin first reported a position in IMUC in Q3 2013 and held it in 12 quarters. The position peaked at $99K in Q1 2018. 3 funds tracked by Wall St. Rank hold IMUC as of Q4 2018.
- Ken Griffin reported no remaining ImmunoCellular Therapeutics, Ltd. position as of Q4 2018 after selling out during the quarter.
- Ken Griffin sold 69,746 ImmunoCellular Therapeutics, Ltd. shares in Q4 2018, an estimated $15K.
- Ken Griffin first reported a position in ImmunoCellular Therapeutics, Ltd. in Q3 2013 and held it in 12 quarters.
- Ken Griffin's ImmunoCellular Therapeutics, Ltd. position peaked at $99K in Q1 2018.
- 3 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics, Ltd. as of Q4 2018.
Based on Citadel Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.